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A melanin-mediated cancer immunotherapy patch
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Melanin is capable of transforming 99.9% of the absorbed sunlight energy into heat, reducing the risk of skin 
cancer. We here develop a melanin-mediated cancer immunotherapy strategy through a transdermal microneedle 
patch. B16F10 whole tumor lysate containing melanin is loaded into polymeric microneedles that allow sustained 
release of the lysate upon insertion into the skin. In combination with the near-infrared light irradiation, melanin 
in the patch mediates the generation of heat, which further promotes tumor-antigen uptake by dendritic cells, 
and leads to enhanced antitumor vaccination. We found that the spatiotemporal photoresponsive immunother-
apy increases infiltration of polarized T cells and local cytokine release. These immunological effects increase the 
survival of mice after tumor challenge and elicited antitumor effects toward established primary tumor and dis-
tant tumor. Collectively, melanin generates local heat, boosts T cell activities by transdermal vaccines, and pro-
motes antitumor immune responses.
INTRODUCTION
Emerging technologies associated with immunotherapy hold tremen-
dous promise in cancer therapy (1). Micro- or nanoformulations or 
engineered immune cells can be used to deliver a variety of immuno-
modulators (2, 3). Scaffolds, such as hydrogel, have also been devel-
oped to generate an immunogenic microenvironment that recruits 
and activates immune cells in situ (4–7). Moreover, T cell engineer-
ing that incorporates antibodies or therapeutics facilitates immune 
targeting and treatment (8–11). Also, dendritic cell (DC)–based vacci-
nation can effectively capture antigens to improve the effectiveness 
of the immune response and is a powerful tool for cancer therapy 
(12–16). However, engineering of DCs often involves complex and 
expensive ex vivo manipulation (4, 17). In addition, the limited lymph 
node–homing capability of ex vivo manipulated DCs is, at least in part, 
responsible for the limited anticancer efficacy (18). Vaccination with 
whole tumor antigens provides a broad source of tu mor-associated 
antigens that elicit substantially enhanced immune responses com-
pared with narrowly defined tumor antigens (19). Moreover, present-
ing a broad spectrum of immunogenic epitopes not only augments 
the immunity mediated by the DC antigen uptake and processing but 
also improves the direct activation of CD4+ T helper and CD8+ cy-
totoxic T lymphocytes (7, 20).
Here, we describe a B16F10 melanoma vaccine patch that targets 
antigen-presenting cells (APCs) directly via transdermal delivery of 
tumor lysates combined with melanin (Fig. 1A). This vaccine in-
volves the encapsulation of inactive whole tumor lysate that is grad-
ually released by an intradermal microneedle (MN) patch inserted 
into the skin. MNs facilitate the uptake and presentation of antigens 
by DCs and, in turn, promote immune activation through the ex-
tensive network of lymphatic vessels in the dermis (21–23). At the 
same time, the presence of melanin, the existing natural biological 
pigment in the whole tumor lysate, allows the local release of heat 
via remotely controllable near-infrared (NIR) light emission. Local 
heat causes the release of inflammatory cytokines that attract immune 
cells, generation of immunogenic substrates such as extracellular 
heat shock proteins (HSPs), reactive oxygen species (ROS), antigen 
adjuvants, and some other danger signals that activate the immune 
system (24, 25). The mild increase in the local temperature of the 
interstitial tissues also contributes to the increased blood and lym-
phatic flow that facilitates the migration of APCs and T cells (24) and 
finally initiates B16F10-specific immune responses (23, 26). The in-
creased blood flow may also allow the recruitment of other cell sub-
sets such as natural killer (NK) cells (7, 27, 28). We found that the 
administration of the vaccine MN patch generated robust innate 
and adaptive immune responses and induced tumor regression in 
the B16F10 melanoma model. Moreover, the NIR-enhanced trans-
dermal vaccination delayed the growth of distant tumor and improved 
long-term survival, paving a strong rationale for pursuing this strategy 
in clinical studies.
RESULTS
Preparation and characterization of the cancer 
immunotherapy patch
We first investigated whether the tumor lysate can be loaded and 
released from transdermal MN patches in a sustained manner. We 
fabricated the MN patch within a micromold to form hyaluronic 
acid–based MNs that encapsulate the whole tumor lysate (with 
melanin) and adjuvants, such as granulocyte-macrophage colony- 
stimulating factor (GM-CSF) (29, 30). Patches with and without 
tumor lysate were illustrated from the axial and transverse perspec-
tives, respectively (Fig. 1B). An array of 15 × 15 MNs was assembled 
on a 9 mm by 9 mm patch with a center-to-center interval of 600 m. 
The detailed dimensions of the MNs were visualized by the scanning 
electron microscopy (Fig. 1C). Each MN had a conical construction 
with a diameter of 300 m at the base, a height of 800 m, and a sharp 
tip tapering to a 5-m radius of curvature. Upon loading with the 
tumor lysate, MNs appeared notably darker than the blank hyaluron-
ic acid–based MNs because of the presence of melanin in the patch 
(31, 32). The amount of melanin was around 50 g per patch, which 
is within the safe dosage range of a single administration (33). A 
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representative MN was constructed with rhodamine B–labeled hyal-
uronic acid encapsulating tumor lysate with actin filaments and 
DNA stained with phalloidin and Hoechst, respectively (Fig. 1D). A 
fluorescent view of the array further showed the uniform loading of 
tumor lysate and alignment of the MNs (Fig. 1E). The MN under-
went failure at 0.39 N in strain testing while being compressed to a 
quarter of its height (fig. S1), demonstrating sufficient strength for 
potential skin insertion without buckling (34).
Next, we evaluated the effects of the NIR laser irradiation on 
melanin-induced heat generation. The temperature variations of the 
MNs were recorded in real time using an infrared thermal camera 
(Fig.  2A). Compared with the transparent hyaluronic acid–based 
MNs, the surface temperature of the MNs loaded with tumor lysate in-
creased dramatically within 1 min because of the melanin-induced 
light-to-heat transduction (Fig. 2B). NIR irradiation at 808 nm could 
be absorbed by the melanin contained in the tumor lysate as demon-
strated by the melanin’s absorption spectrum (fig. S2A). The ab-
sorption coefficient of the melanin content in the tumor lysate was 
also comparable with that of the synthetic melanin (fig. S2A and 
table S1). Despite the temperature increase, the morphology of the 
MNs remained unchanged, and the photothermal property of mela-
nin was stable during the treatment (fig. S2B) (35). The heating be-
havior of the MN patch was also maintained when repeated NIR 
light exposures were performed (fig. S3). Furthermore, the steady 
state of the patch’s surface temperature was lysate concentration– 
and NIR light intensity–dependent, whereas the thickness of the MN 
backing had a minimum effect (fig. S4 and Fig.  2C). The surface 
temperature of the patch could be controlled under hyperthermia 
(42°C) to minimize the potential thermal-induced denatura tion of 
the tumor antigen and other biomolecules.
In vitro activation of DCs in response to vaccine MN
GM-CSF that serves as a potent cytokine for DC recruitment and ac-
tivation was physically encapsulated into MN tips by cross-linking 
Fig. 1. Schematic of melanin-mediated cancer immunotherapy through a transdermal MN-based vaccine patch. (A) Schematic illustration of MN-based transdermal 
vaccination. TH cell, T helper cell; Tc cell, cytotoxic T cell. (B) Photograph of representative MN patches without (W/o) melanin and with (W/) melanin (scale bar, 4 mm). 
(C) Scanning electron microscopy image of the MN patch (scale bar, 400 m). (D) Fluorescence cross-sectional images of a representative MN. Actin filaments in cells were 
visualized by Alexa Fluor 488 phalloidin (green), cell DNA fragments were stained with Hoechst (blue), and hyaluronic acid polymer matrix was labeled with rhodamine B 
(red) (scale bar, 200 m). (E) Fluorescence imaging of a representative MN patch that contained the Alexa Fluor 488 phalloidin–labeled tumor lysate and rhodamine
B–labeled hyaluronic acid (scale bar, 400 m).
methacrylated hyaluronic acid upon ultraviolet irradiation. We 
found that 60% of the bioactive GM-CSF was released from MN 
within 48 hours (fig. S5, A and B), whereas sustained release of the 
tumor lysate protein was observed over 5 days (Fig. 2D). Incorpora-
tion of the NIR treatment did not alter the release profiles of GM-CSF 
and tumor lysate (fig. S5, C and D). Scanning electron microscopy 
images of vaccine MNs showed a gradual dissociation of tips over 
time (fig. S6).
To evaluate whether GM-CSF in MNs provided signaling cues 
that could efficiently promote DC maturation, we exposed bone 
marrow–derived DCs to the dissolved MN suspension. The percent-
age of matured DCs (CD80+ and CD86+) substantially increased from 
36.7 ± 2.3% to 48.9 ± 3.1% after treatment with tumor lysate– and 
GM-CSF–loaded MNs with 10 min of NIR laser irradiation (Fig. 2E) 
(36). The effect of varying NIR laser irradiation time on the activation 
of DCs was also measured. Ten minutes of NIR irradiation allowed 
optimal DC activation as compared with samples treated with 5 or 
15 min (Fig. 2E). Only 20 min of NIR exposure slightly impaired DC 
viability and functionality (fig. S7). DCs in all other experimental 
conditions of either MN suspension or 10 min of NIR irradiation 
exhibited high viability (Fig. 2, F and G, and fig. S8).
In vivo efficacy of MN-mediated immunization upon NIR
To characterize the in vivo efficacy of MN-based immunization, we 
transdermally treated C57BL/6J mice with vaccine MN patch loaded 
with B16F10 whole tumor lysate containing 1.5 mg of extracted pro-
tein. We measured the magnitude and duration of the immune re-
sponse after NIR irradiation and subsequent tumor challenge (Fig. 3A). 
MN patches were applied on the mice skin of the caudal-dorsal area 
for about 10 min and further affixed using the Skin Affix surgical 
Fig. 2. Characterization of the light-responsive transdermal MNs. (A) Surface temperature changes of the MNs with or without tumor lysate in real time with continuous 
808-nm NIR irradiation at 1.0 W/cm2, characterized by an infrared thermal camera (scale bars, 1 mm). (B) Quantitative surface temperature changes of representative
MNs with continuous NIR irradiation at 1.0 W/cm2 (n = 3). (C) Quantitative temperature changes of representative MN patch with increasing laser power flux (n = 3). (D) In 
vitro collective release of tumor lysate proteins from the MN patch (n = 3). (E) In vitro activation of DCs in response to MNs loaded with tumor lysate and GM-CSF or LPS 
and exposed to NIR irradiation for different time (n = 3). (F) LIVE/DEAD assay of DCs after treatments with (i) blank MN, (ii) 10 min of NIR, (iii) MN, and (iv) MN and 10 min 
of NIR. Live cell (green), dead cell (red). (G) Quantification of DC viability after treatments. Data points represent mean ± SD (n = 3). Error bars indicate SD. Statistical signif-
icance was calculated by Student’s t test [not significant (NS), P > 0.05; *P < 0.05].
adhesive. Staining with trypan blue and hematoxylin and eosin 
(H&E) indicated successful penetration of MNs in the excised skin 
(fig. S9). The transdermal patch remained in the skin for at least 
5 days (Fig. 3B). We then performed localized NIR irradiation on 
the MN region for 10 min daily for 5 days (MN + NIR). Control mice 
were treated with either vaccine MN patch without NIR irradiation 
(MN), MN patch loaded only with melanin (melanin), or MNs con-
taining only hyaluronic acid with NIR irradiation (blank).
Temperature changes in the regional skin surface after vaccine 
MN insertion were recorded in real time using an infrared thermal 
camera. Light-to-heat transduction upon NIR irradiation caused a 
local heating effect observed in mice treated with vaccine MNs 
(Fig. 3C). The melanin in the vaccine patch mediated the transder-
mal heating at temperatures between 38° and 42°C within 30 s. Mild 
hyperthermia at the local treated site was similarly observed in mice 
treated with synthetic melanin–loaded MNs (fig. S10A). In contrast, 
mice treated with blank MNs and NIR and mice implanted with 
loaded MNs but without NIR showed limited variations in skin sur-
face temperature within the normal range of 33° to 36°C (Fig. 3C).
In a prophylactic mouse model, mice were implanted with B16F10 
melanoma cells 10 days after vaccination (Fig. 3D). All mice treated 
with the blank MNs had appreciable tumor growth within 15 days 
after tumor cell inoculation and required euthanasia by day 25. MNs 
loaded with melanin and treated with NIR irradiation slightly im-
proved the survival of the mice because some mice survived to day 
25 (fig. S10, B and C). Similarly, MNs loaded with tumor lysate and 
melanin but without NIR irradiation caused tumor protection in 
13% of the mice until day 30 (Fig. 3, E and F). In sharp contrast, 
mice receiving the combined vaccination (MNs loaded with tumor 
lysate and GM-CSF and NIR irradiation) showed long-term survival 
with complete tumor rejection in 87% of the treated mice (Fig. 3, E 
and F, and fig. S11). Bioluminescence imaging of the B16F10 melanoma– 
bearing mice confirmed significant inhibition of tumor growth (Fig. 3G 
and fig. S12). This was further evidenced by the measurement of 
tumor weight (fig. S13) and histologic analysis (fig. S14A).
We next assessed the requirement of immune cells for the anti-
tumor effects observed by combined vaccination–based treatments. 
Depletion of CD11c+ DCs in diphtheria toxin receptor (DTR) mice 
was sufficient to abrogate the antitumor effect of the vaccine MN 
(Fig. 3, E and F). A study in Rag1−/− mice deficient in T cells and B 
cells showed a significant loss of tumor growth suppression during 
treatment with combined vaccination (fig. S11). Selective depletions 
of CD8+ and CD4+ T cells before combined MN vaccination were 
also studied. Eliminating CD8+ T lymphocytes showed no significant 
Fig. 3. Vaccine MN confer protective innate and adaptive immunity. (A) Schematic illustration of MN cancer immunotherapy. (B) Characterization of the MNs after 
insertion. (i) Photo of mouse dorsal skin (the area within the red line) that was treated transdermally with one MN patch and (ii) fluorescence signals of Cy5.5-labeled MN 
patch over time. (C) Surface temperature changes of individual animal after MN insertion into the skin measured by an infrared thermal camera. (D) Schematic represen-
tation of the B16F10 vaccine tumor model. (E) Average tumor volumes in treated mice after tumor challenge. (F) Kaplan-Meier survival curves for treated and control mice. 
Data points represent mean ± SD (n = 8). Error bars indicate SD. Statistical significance was calculated by Student’s  test and log-rank test (**P < 0.01; ***P < 0.001). (G) In 
vivo bioluminescence imaging of the B16F10 melanoma in different experimental groups and at different time points after tumor challenge. Three representative mice 
per treatment group are shown. The tumor growth in (E) to (G) was measured 10 days after tumor cell inoculation.
tumor regression compared with blank control (fig. S15). When anti- 
CD4 antibody was given to the mice, there was a decrease (P < 0.01) 
in tumor size in contrast to the control, suggesting the benefit of 
CD4 T cells to a lesser extent than CD8 T cells for the antitumor 
response (fig. S15). The depletion of B cells and NK cells also had 
deleterious impact on the immune response while not diminishing 
the vaccination effect toward tumor challenge (fig. S15). Together, these 
results showed that the MN vaccination was associated with CD11c+ 
DCs and other immune cells such as T cells, B cells, and NK cells.
Loading of GM-CSF in the MNs played an important role in the 
local recruitment of DCs [CD11c+, paired immunoglobulin (Ig)–like 
receptors (PIRs) of activating-A/B+] (Fig. 4, A and C). Three days 
after combined vaccination, a 5.9-fold increase in accumulated DCs 
was observed in the skin section compared with mice treated with 
blank MN. NIR further augmented the effect of GM-CSF–loaded 
MNs on recruiting DCs (Fig. 4C). Increased localization of NK cells 
was also observed (Fig. 4, B and D). In addition, the elevated local 
microcirculatory blood perfusion observed after NIR and MN treat-
ment could contribute in enhancing the migration of immune cells 
(table S2 and fig. S16). Tumor infiltration by T cells upon treatment 
was analyzed by flow cytometry on day 15 after tumor inoculation. 
About 9.8-fold increase in CD8+ T cells was observed in mice re-
ceiving the combined vaccination compared with control mice, 
whereas MN-only group showed a 5.8-fold increase (Fig. 5A). Fur-
thermore, staining with H-2Db gp100 tetramers identified B16F10- 
specific CD8+ T cells in tumors of treated mice (37). The percentage 
of tetramer-positive CD8+ T cells was found to be greater in the 
MN-treated mice compared with control mice lacking immuniza-
tion (fig. S17). Mice with combined treatment or MN-only treatment 
exhibited 1.5- and 1.3-fold increases in activated DCs (CD80+ and 
CD86+), respectively, in regional skin as compared with control mice 
(Fig. 5B). Immunofluorescence staining and in situ cell apoptosis 
confirmed the results obtained with flow cytometry (Fig. 5C and fig. 
S14B). Local immune activation was associated with systemic immune 
responses. We measured an eightfold increase in IgG titers in the 
serum of immunized mice as compared with mice treated with blank 
control (Fig. 5D). NIR treatment promoted further increase in IgG 
titers by day 15 and prolonged immune responses compared with 
Fig. 4. Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. (A) Representative quantitative analysis of DCs (CD11c+ and 
PIR-A/B+) infiltrated in the skin 3 days after treatments as assessed by flow cytometry. The indicated samples were treated with blank MN (blank), vaccine MN (MN), MN 
loaded with tumor lysate without GM-CSF and treated with NIR (NIR), and vaccine MN and treated with NIR (MN + NIR). a.u., arbitrary units. (B) Representative quantitative 
analysis of NK cells (CD49b+) in the skin upon transdermal cancer immunotherapy as assessed by flow cytometry. (C and D) Immunofluorescence staining and quantitative 
analysis of (C) CD11c+ DCs (scale bar, 100 m) and (D) CD49b+ NK cells (scale bar, 100 m). Statistical significance was calculated by Student’s t test (*P < 0.05; **P < 0.01). 
Asterisks indicate significant differences between the MN + NIR group and all other treatment groups. Data points represent mean ± SD (n = 3). Error bars indicate SD.
control groups (fig. S18). The in vitro analysis of splenocytes re-
vealed 10-fold higher frequency of T cells responding to B16F10 
tumor lysate in mice receiving the combined vaccination (Fig. 5E).
To examine that the light-to-heat transduction induced the produc-
tion of danger signals and proinflammatory cytokines, we first mea-
sured local levels of ROS in the MN-treated surrounding tissue by 
flow cytometry. Samples from mice receiving the combined treat ment 
showed about fourfold increase in ROS levels compared with the un-
treated group, whereas 1.5-fold increase was observed compared with 
the MN control without the NIR irradiation (fig. S19). In line with the 
elicitation of danger signals, combined vaccination caused the expres-
sion of HSP70 and HSP90 (Fig. 5F and fig. S20) (38). Danger signals 
from the local tissue and the antigenic molecules promote proinflam-
matory cytokine production (39). Consistent with this effect, we found 
local increases of interferon- (IFN-), tumor necrosis factor– 
(TNF-), and interleukin-6 (IL-6) in mice treated with the combined 
vaccination compared with MN controls (Fig. 5G and fig. S21).
Efficacy of MN patch in distant tumors
We further analyzed whether the local vaccination confers protection 
toward secondary tumors distant from the NIR- and MN-treated site 
(Fig. 6A). Local NIR irradiation and MN treatment were performed 
only on the left-side tumor in B16F10 mice bearing bilateral tumors. 
Right-side tumor was not injected and was shielded from light 
(Fig. 6B). We observed that the tumor sizes and bioluminescence 
signals decreased significantly on both sides of the mice that had the 
combined vaccination (Fig. 6, C to G). Meanwhile, substantial in-
crease of activated DCs in the regional lymph node (Fig. 5B) and 
enhanced cytotoxic responses to B16F10 cells of the splenocytes 
in vitro (Fig. 5E) indicated that systemic antitumor effect could 
be achieved by the transdermal immunotherapy. This effect was 
parallel by fivefold increases in CD8+ T cell infiltration compared 
with control, which was consistent with the role of immune cells for 
antitumor efficacy (Fig. 6D). Distant metastases were not observed 
in the lungs of the mice with combinational treatment (fig. S22). 
Fig. 5. Immunologic responses after the MN-mediated cancer immunotherapy. (A) Representative quantitative analysis of T cells (gated on CD3+ T cells) in 
treated tumors analyzed by flow cytometry. (B) Representative quantitative analysis of activated DCs (CD86+ and CD80+) in the draining lymph nodes analyzed by 
flow cytometry. Data points represent mean ± SD (n = 8). (C) Immunofluorescence staining of the tumors showing CD4+ T cell and CD8+ T cell infiltration (scale bars, 
100 m). (D) Quantification of IgG1 subtypes in serum collected at day 10. Data points represent mean ± SD (n = 8). (E) Cytotoxic responses of splenocytes against 
B16F10 cells in vitro. Data points represent mean ± SD (n = 6). (F) Immunofluorescence staining of HSP70 (green) in the regional skin with actin filaments visualized 
by Alexa Fluor 660 phalloidin (red) and cell nuclei stained with Hoechst (blue) (scale bars, 100 m). (G) In vivo local detection of cytokines from extracted patches at 
day 3. Statistical significance was calculated by Student’s t test (*P < 0.05; **P < 0.01). Data points represent mean ± SD (n = 8). Error bars indicate SD. CTL, cytotoxic 
T lypmphocyte.
Body weight measurements indicated that the treated mice gained 
weight within the normal ranges (Fig.  6H). When the mice were 
vaccinated with tumor lysate of a different melanoma cell type 
[BRAFV600EPTEN −/− Duke-clone 6 cell line (BPD6 or BP), syngene-
ic with C57BL/6J] (40, 41), minimal changes in the B16F10 tumor 
growth were observed (Fig. 6I), indicating the specificity of the im-
munological memory. Similarly, when vaccinated mice were rechal-
lenged with B16F10 cells or BP cells, tumor protection was observed 
only in mice challenged with B16F10 (Fig. 6, J and K, and fig. S23).
Efficacy of MN patch in other tumor models
To demonstrate that the potency of proposed vaccination is not lim-
ited to the B16 melanoma model in which there is an up-regulation 
of the melanogenesis, we used a BRAFV600E-mutated BP melanoma 
in C57BL/6J mice and a triple-negative breast cancer 4T1 carcinoma 
tumor in BALB/cJ mice. Studies of MN loaded with synthetic melanin 
(with the same amount of pigment as quantified by spectrophotom-
etry; table S1) and tumor lysate showed similar hyperthermic effect 
and enhanced immune responses with combined vaccination (fig. 
S24). Tumor regression and long-term survival were also achieved. 
Vaccination with the combined approach rendered 75 and 87% of 
mice resistant to BP and 4T1 engraftment, respectively (Fig. 7, A and 
B, and fig. S25). In the tumor-bearing mice, MN and NIR treat ments 
induced complete remissions in 87 and 37% of mice engrafted with 
BP and 4T1 cells, respectively (Fig. 7, C and D, and fig. S25). Analysis 
of the local HSP70 expression showed a 2.5-fold increase in BP and 
a 4-fold increase in 4T1 models upon combined vaccination com-
pared with the MN alone (fig. S26). Production of proinflammatory 
cytokines was also induced with the combined treatment, resulting in 
enhanced DC activation (figs. S27 and S28). Treatments were well 
Fig. 6. Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. (A) Schematic representation of the B16F10 tumor model. 
(B) Photograph of a mouse before and after MN administration. Red arrows indicate established tumors on both sides. L, left; R, right.The red line indicates the MN injec-
tion site. (C) Tumor weights in different experimental groups (n = 3). (D) Tumor-infiltrating CD8+ T cells after treatments in different experimental groups (n = 6). Asterisks 
in (C) and (D) indicate statistically significant differences between blank MN and other groups. (E) Images of tumors extracted from treated mice indicated by the labels 
in (D). (F) In vivo bioluminescence imaging of treated B16F10 melanoma at different time points after treatment. One representative mouse per treatment group is shown. 
(G) Average tumor volumes in treated mice. (H) Body weights of treated mice (n = 6). (I) Average B16F10 tumor volumes in mice treated with MNs loaded with BP lysate 
with melanin and blank MN (n = 8). (J) Average tumor volumes in vaccinated mice rechallenged with either B16F10 cells or BP cells on day 80. (K) Kaplan-Meier survival 
curves for rechallenged mice. Data points represent mean ± SD (n = 8). Error bars indicate SD. Statistical significance was calculated by Student’s t test and log-rank test 
(NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001).
tolerated and did not cause weight loss or clinical signs of distant 
metastasis (figs. S29 and S30).
DISCUSSION
In the current study, we have integrated the B16F10 whole tumor 
lysate and GM-CSF into a transdermal MN patch to sustain the de-
livery of the cancer vaccine and target immune cell populations in the 
epidermis. By incorporating the melanin, we have demonstrated that 
the combined vaccine facilitated local immune activation upon NIR 
irradiation through the recruitment of DCs and other immune cells. 
Compared with other photosensitizing agents (42, 43), melanin is a nat-
ural pigment with high biocompatibility and broad absorption spec-
trum. The efficient light-to-heat transduction mediated by melanin 
contributed to the rapid increase in skin temperature toward 42°C.
The combined treatment caused long-term survival with tumor 
rejection in 87% of vaccinated C57BL/6J mice. Complete tumor pro-
tection was further observed in mice rechallenged with B16F10 tumor 
cells. After NIR treatment, the elevated local microcirculatory blood 
perfusion was associated with the migration of local DCs and NK 
cells. Depletion of B cells, NK cells, and T cells attenuated the treatment 
efficacy in vaccinated mice, highlighting the relevance of the immune 
control in the tumor development. In accordance, the production of dan-
ger signals and proinflammatory cytokines triggered the immune activa-
tion. We have identified the elevated HSP70 and HSP90 expression and 
ROS levels in the surrounding tissues. This effect was also associated with 
local enrichment of IFN-, TNF-, and IL-6. Characterization of other rel-
evant danger signals and antigen adjuvants needs to be further examined.
In summary, the whole tumor lysate with melanin in a light- 
irradiated MN patch generates a hyperthermic-mimicking micro-
environment that effectively recruits and activates immune cells at 
the vaccination site. As a result, the melanin-mediated patch prevents 
tumor engraftment in prophylactic models and causes sustained 
tumor regression in tumor-bearing mice. In addition, the natural 
melanin used in this treatment can also be extended to other bio-
logical pigments, such as carotenoid, xanthophylls, and bilirubin, for 
photomediated therapy. This method is also adaptable to deep- 
tissue photoacoustic imaging, biological labeling, and targeting a 
variety of diseases in a photo-/thermoresponsive manner (44–46 ). 
Nevertheless, the parameters associated with this immune activa-
tion need further optimization, for instance, the duration of NIR 
irradiation and the selection of light wavelength, as well as the treat-
ment site. For the future study of the proposed approach, personal 
neoantigens and checkpoint inhibitors could be incorporated into 
the MNs to further enhance treatment specificity and efficacy (47). 
For the potential translation of the vaccine patch, it relies profoundly 
on a prolonged safety evaluation of the local and systemic toxicity, 
as well as other potential side effects.
MATERIALS AND METHODS
Study design
The objective of this study was to assess the effect of a melanin-mediated 
transdermal patch on cancer vaccine–based immunotherapy. The 
B16F10 whole tumor lysate containing melanin was integrated into 
an MN patch that allows controlled release of the cancer vaccine. 
Fig. 7. Antitumor effect of local cancer immunotherapy treatment in various tumor models. (A) Average tumor growth and Kaplan-Meier survival rate of vaccinated 
C57BL/6J mice after BP tumor cell challenge. Mice were pretreated with blank MN (blank), MN loaded with BP tumor lysate and melanin (MN), or loaded MN combined 
with NIR irradiation (MN + NIR). (B) Average tumor growth and Kaplan-Meier survival rate of vaccinated BALB/cJ mice after 4T1 tumor cell challenge. Mice were pretreat-
ed with blank MN, MN loaded with 4T1 tumor lysate and melanin, or loaded MN combined with NIR irradiation. (C) Average tumor growth and Kaplan-Meier survival rate 
of C57BL/6J mice bearing established BP tumors. Mice were treated with blank MN, MN loaded with BP tumor lysate and melanin, or loaded MN combined with NIR irra-
diation. (D) Average tumor growth and Kaplan-Meier survival rate of BALB/cJ mice bearing established 4T1 tumors. Mice were treated with blank MN, MN loaded with 4T1 
tumor lysate and melanin, or loaded MN combined with NIR irradiation. Data points represent mean ± SD (n = 8). Error bars indicate SD. Statistical significance was calcu-
lated by Student’s t test and log-rank test (*P < 0.05; **P < 0.01; ***P < 0.001).
Upon NIR light irradiation on the patch, the local heating effect on 
boosting immune responses was evaluated. Mice subjects were pur-
chased from the Jackson Laboratory, weighed, and randomly divided 
into different experimental groups. The numbers of sampling and 
experimental replicates were included in each figure legend.
Preparation and characterization of MNs
All MNs were prepared using silicone molds with arrays of conical 
holes machined by laser ablation (Blueacre Technology Ltd.). Each MN 
had a 300 m by 300 m round base tapering to a height of 800 m with 
a tip radius of around 5 m. MNs were arranged in a 15 × 15 array with 
a 600-m center-to-center spacing. GM-CSF solution (0.1 mg/ml, 10-l 
final volume) was directly deposited by pipetting onto each silicone 
micromold surface, followed by vacuum (600 mmHg) condition for 
5 min to allow the solution to flow into the cavities. After that, 0.2 ml of 
4.0 weight % (wt %) methacrylated hyaluronic acid solution mixed with 
N,N′-methylenebisacrylamide (2.0 wt %) and photoinitiator (Irgacure 
2959; 0.05 wt %) were directly deposited by pipetting onto each silicone 
micromold surface, followed by vacuum (600 mmHg) condition for 
5 min and centrifugation at 2000 rpm for 5 min (Hettich Universal 32R 
centrifuge). GM-CSF layer was cross-linked via ultraviolet irradiation 
(wavelength, 365 nm) for 10 s, and a piece of 4 cm by 9 cm silver adhe-
sive tape was applied around the 2 cm by 2 cm micromold baseplate. 
Three milliliters of homogenized B16F10 tumor lysate (containing 1.5 mg 
of extracted tumor lysate proteins) in 4.0 wt % mixed methacrylated 
hyaluronic acid solution was added to the prepared micro mold reser-
voir. We also used hyaluronic acid solution with different concentrations 
of tumor protein from 0.25 to 0.5 to 1.0 mg/ml. Protein concentration 
was quantified by measuring extracted protein content in the tumor 
lysate supernatant using T-PER (tissue protein extraction reagent) and 
Bradford assay before the MN fabrication. For the BP or 4T1 tumor 
lysate–loaded MNs, 50-g melanin was dissolved in 4.0 wt % mixed 
methacrylated hyaluronic acid solution with tumor lysate (containing 
1.5 mg of extract tumor lysate proteins, 3.0-ml final volume) to fabri-
cate the MN matrix. For the blank MNs without tumor lysate, mixed 
methacrylated hyaluronic acid solution was used without the tumor 
lysate. For the melanin-loaded MNs, 50-g melanin was dissolved in 
4.0 wt % mixed methacrylated hyaluronic acid solution to fabricate the 
MN matrix. The stock melanin solution (100 mg/ml) was prepared by 
dissolving melanin in 1.0 M sodium hydroxide and heating to 99°C for 
10 min. Final formulation was dried at 25°C in a vacuum desiccator 
overnight. After desiccation was completed, needle arrays were careful-
ly separated from the silicone molds and cross-linked via ultraviolet 
irradiation. The needle base was tailored into a square shape. Fluores-
cent MNs were fabricated with phalloidin-labeled tumor lysate and 
rhodamine B– or Cy5.5-labeled hyaluronic acid. The preparation and 
storage of MNs were under sterilized condition. Morphology of MNs 
was characterized on a FEI Verios 460L field-emission scanning elec-
tron microscope operating at 20 kV after sputter coating with gold/
palladium at the Analytical Instrumentation Facility. Cross sections of 
MNs were obtained by cutting 5-m slides using Thermo Fisher Scien-
tific HM525 NX Cryostat and stained with Alexa Fluor 488 phalloidin 
and Hoechst. Fluorescence images of MNs were taken by the Olympus 
IX70 multiparameter fluorescence microscope.
NIR-responsive property of MN
To evaluate the property of the MN patch in response to NIR light irra-
diation, we irradiated samples with 808-nm NIR laser light. The diode 
infrared laser module (Opto Engine LLC, MDL-N-808) was approved 
by a laser safety officer of the North Carolina State University (NC State) 
Environmental Health and Safety Center. The MN patches were placed 
on a piece of white paper with the needle tips facing down. The laser 
wire was fixed in place using a plate stand with a support rod and a 
clamp. The distance between the patch and spotlight was fixed at 10 cm, 
and the spot size was ~1 cm2. The output energy of the diode infrared 
laser module was adjusted within 1.0 W and led to the intensity per unit 
area (E = I/d2) of 1.0 W/cm2 (at 808 nm). The NIR light was irradiated 
continuously or intermittently as needed. Surface temperature changes 
of the MN patch backing were recorded, and the highest temperature 
was controlled below 42°C in real time using a thermal imager (FLIR E4) 
and a noncontact infrared thermometer gun (Leegoal). For intermittent 
irradiation, the MNs were repeatedly exposed to the laser (1.0 W/cm2), 
and the local temperature reached about 42°C for 1 min. Subsequently, 
the laser was turned off for 1 min. This cycle was repeated four times 
to assess the responsive behavior of MN patch under repeated NIR 
irradiation. For the continuous irradiation, samples with different 
parameters were tested. The effect of melanin content on the light- 
responsive behavior was tested on MNs loaded with tumor lysate of 
different protein concentration or blank MN with hyaluronic acid. 
Quantitative surface temperature changes of the representative MNs 
were recorded under continuous NIR irradiation at 1.0 W/cm2. In a 
separate experiment, the laser power flux was controlled. During con-
tinuous NIR exposure for 2 min, the maximal temperature of the MN 
surface was recorded and plotted. The effect of MN backing thickness 
on the light-responsive behavior was tested on MNs with continuous 
NIR irradiation at 1.0 W/cm2. The thickness of the MN patch was mea-
sured with an average value of 181 m and an SD of 12.5 m using a 
digimatic indicator (Mitutoyo Corp. ID-C112E Series 543). MN patch 
samples with different backing thicknesses (169, 175, 179, 181, and 
202 m) were used.
In vitro DC activation
Bone marrow was collected by flushing the femur and tibia with 
complete RPMI 1640 containing 10% fetal bovine growth serum. Af-
ter lysis of red blood cells (lysate solution, Cwbiotech), 1 × 106 bone 
marrow cells were seeded in six-well culture dishes with 3.0 ml of 
the culture medium containing GM-CSF (20 ng/ml) and 50 M 
-mercaptoethanol (Bio-Rad, Hercules, CA, USA). On day 3, an ad-
ditional 4.0 ml of the same medium with GM-CSF was added into 
the plates. On day 6, half of the culture supernatant was collected and 
centrifuged. Cells were resuspended in RPMI 1640 and added back into 
the original plates. On day 7, nonadherent cells were collected and 
used as bone marrow–derived DCs for further research use. Another 
murine DC line JAWS II cells were cultured in minimum essential 
medium Eagle alpha modification (Sigma-Aldrich) supplemented with 
GM-CSF (5 ng/ml). DCs were left unstimulated or stimulated for 
12 hours with blank MN (100 g/ml) or tumor lysate–loaded MN 
release medium or lipopolysaccharide (LPS; 100 ng/ml). After the 
stimulation, the cells were exposed to NIR irradiation (1.0 W/cm2) 
at a distance of 10 cm for 0, 5, 10, 15, and 20 min, respectively. After cell 
incubation for 4 hours, the supernatants were collected and measured 
by IL-12 p70 mouse ELISA kit (Thermo Fisher Scientific, MC0121). The 
cells were washed and stained with LIVE/DEAD assay (Thermo Fisher 
Scientific, L3224) and CD80+, and CD86+ maturation marker- specific 
antibodies and subsequently analyzed by the confocal microscopy 
and flow cytometer. Both bone marrow–derived DCs and JAWS II 
cell line were used for characterization of DC activation. The LIVE/
DEAD assay imaging data were obtained from the JAWS II cell line.
Mice and in vivo tumor models
Female C57BL/6J mice, BALB/cJ mice, CD11c-DTR transgenic mice 
[B6.FVB-Tg(Itgax-DTR/EGFP)57Lan/J; stock no. 004509], and 
Rag1−/− knockout mice (B6.129S7-Rag1tm1Mom/J; stock no. 002216) 
were purchased from the Jackson Laboratory. Mice were weighed and 
randomly divided into different groups. On day 0, healthy mice were 
treated with MNs loaded with tumor lysates and GM-CSF, blank MNs 
loaded with synthetic melanin without tumor lysates, or blank MNs 
containing hyaluronic acid only (blank). MN patches were applied into 
the skin of the caudal-dorsal area for about 10 min and further fixed 
using Skin Affix surgical adhesive (Medline Industries Inc.). After in-
jection of the MNs, NIR irradiation was performed on the localized 
MN region for 10 min each day for five successive days after immuni-
zation (MN + NIR). The diode infrared laser module at 808 nm (Opto 
Engine LLC, MDL-N-808) was approved by a laser safety officer of the 
NC State University Environmental Health and Safety Center. Mice in 
the control groups were treated with either vaccine MNs without NIR 
irradiation (MN), blank MNs loaded with synthetic melanin without 
tumor lysate with NIR irradiation (melanin), or blank MNs containing 
hyaluronic acid only with NIR irradiation (blank). Surface temperature 
changes of the regional skin were recorded and controlled below 42°C 
in real time using a thermal imager (FLIR E4) and a noncontact infra-
red thermometer gun (Leegoal). On day 10, 1 × 106 B16F10 tumor cell 
lines in 25 l of phosphate-buffered saline (PBS) were subcutaneously 
transplanted into the flank of the C57BL/6J mice, CD11c-DTR trans-
genic mice, and Rag1−/− knockout mice. Tumor-free mice were rechal-
lenged with 1 × 106 B16F10 tumor cells in 25 l of PBS 80 days after the 
first tumor inoculation. For the depletion antibody study, we depleted 
specific T cell, B cell, and NK cell populations in mouse models. Mice 
were intraperitoneally given 200 g of antibody purified from mouse 
thymus or spleen dissolved in 200 l of PBS. Antibodies against CD4 
(BioLegend, LEAF 100435), CD8 (BioLegend, LEAF 100735), CD19 
(BioLegend, LEAF 152402), and NK-1.1 (BioLegend, LEAF 108712) 
were administered twice weekly for 3 weeks, starting 1 week before the 
tumor inoculation. Depletions were confirmed by flow cytometry of 
splenic suspension. For another melanoma model, 1 × 106 BP tumor 
cells in 25 l of PBS were subcutaneously transplanted into the flank of 
the C57BL/6J mice. For the carcinoma tumor model, 1 × 106 4T1 tu-
mor cells in 25 l of PBS were subcutaneously transplanted into the 
flank of the BALB/cJ mice. For experimental metastasis model, 1 × 105 
tumor cells were intravenously infused into mice via the tail vein. In 
another set of experiments, tumor cells were subcutaneously trans-
planted into the flank of the mice on day 0. The tumor-bearing mice 
were weighed and randomly divided into four groups when the tumor 
volume reached around 50 mm3 on day 3. After that, the mice were 
peritumorally administrated with sterile MN loaded with tumor lysate 
and GM-CSF (MN) or blank MN containing hyaluronic acid only 
(blank). After that, NIR light was irradiated on the MN patch for 10 min 
during the following 5 days from days 3 to 7. Tumor growth was mea-
sured by a digital caliper or monitored by bioluminescence signals of 
luciferase-tagged cells. The tumor volume (cubic millimeter) was cal-
culated as 1/2 × long diameter × (short diameter)2.
To assess potential toxicity, we monitored mice daily for weight loss. 
H&E staining was performed on the organs collected from the mice 
following the standard procedure (Histology Laboratory at NC State 
College of Veterinary Medicine). Lungs were excised, and macroscopi-
cally visible metastases were counted. The resected primary tumors 
were stored at −20°C for immunofluorescence staining or fixed in 4% 
paraformaldehyde for subsequent analysis.
Identification of DC subsets, T cells, and cytokines
Antibodies used were purchased from Thermo Fisher Scientific and 
BioLegend Inc. Staining antibodies, including CD3 (Thermo Fisher 
Scientific, A18644), CD4 (Thermo Fisher Scientific, A18667), CD8 
(Thermo Fisher Scientific, A18609), CD11c (BioLegend, 117309), CD49b 
(BioLegend, 108909), CD80 (BioLegend, 104707), CD86 (BioLegend, 
105007), PIR-A/B (gp91, BioLegend, 144103), tetramer (MBL Interna-
tional, H-2Db gp100, EGSRNQDWL-P), and fluorogenic CellROX 
Deep Red reagent (BioLegend, C10422) were used for fluorescence- 
activated cell sorting (FACS) and were analyzed following the manu-
facturers’ instructions. Organs (skin, tumor, lymph node, and spleen) 
were harvested and minced into 2- to 4-mm pieces using scissors or 
scalpel blade. A single-cell suspension was prepared in the cell staining 
buffer (BioLegend, 420201). CellROX reagents at predetermined opti-
mum concentrations were added to the cells and incubated on ice for 
20 to 30 min in the dark for ROS detection. The relevant tetramer phy-
coerythrin (PE) was stained at room temperature for 30 min in the dark 
before additional staining with appropriately conjugated fluorescent 
antibodies. Stained cells were analyzed on a FACSCalibur instrument (BD) 
and using FlowJo software. To determine the concentration of different 
cytokines at the vaccine MN site, patch and adjacent tissues were ex-
cised and digested with T-PER (Pierce). Cytokine concentrations in the 
extracted patch were analyzed with a BioLegend’s LEGENDplex bead-
based immunoassays, according to the manufacturer’s instructions.
Statistical analysis
Statistical analysis was evaluated using GraphPad Prism (6.0). Statisti-
cal analysis was performed with paired Student’s t test and analysis of 
variance (ANOVA). P values for Kaplan-Meier curves were calculated 
with log-rank test. P values of 0.05 or less were considered significant.
Study approval
All mouse studies were performed following animal protocols ap-
proved by the Institutional Animal Care and Use Committee at the NC 
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